For The Better

Another phase of sharply accelerating growth is in sight for Nvidia.

The path is clear for even more growth from Novo Nordisk’s top two drugs, Ozempic and Wegovy.

These billionaires are favoring shares of potential AI winners.

The fintech offered a mixed outlook following its first-quarter earnings announcement.

Procter & Gamble’s financial results are still pretty good, but they are getting weaker. The stock appears fairly valued today.

The fourth quarter includes the all-important holiday season, and GoPro ended 2023 on a weak note. That’s not a great sign for 2024.

This company operates in a massive industry, generates excellent profit margins, and is benefiting from the rising effectiveness of artificial intelligence.

The company raised guidance for sales of its drug for relapsing multiple sclerosis.

The company has proven its ability to generate solid ROI over the long run with its investments in AWS.

Super Micro Computer sales are soaring, but investors wanted to see more from the artificial intelligence enabler after its latest earnings release.

Gates’ foundation trust holds stakes in several blue chips, but these smaller positions could be smart picks for growth investors looking for hidden gems.